Depressive effect of an antidepressant: Therapeutic failure of venlafaxine in a case lacking CYP2D6 activity

Annals of Clinical Biochemistry

Volumn 46, Issue 6, 2009, Pages 527-530

  Wijnen, P A H M ^a   Limantoro, I ^a   Drent, M ^a   Bekers, O ^a   Kuijpers, P M J C ^a   Koek, G H ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; FUROSEMIDE; METOPROLOL; PANTOPRAZOLE; ROSIGLITAZONE; SIMVASTATIN; URSODEOXYCHOLIC ACID; VALSARTAN; VENLAFAXINE; ZOPICLONE;

ADULT; AGITATION; ANXIETY; ARTICLE; ASTHENIA; BRADYCARDIA; CASE REPORT; CONFUSION; CONSTIPATION; COORDINATION DISORDER; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; ENZYME ACTIVITY; FATIGUE; FATTY LIVER; FEMALE; GENETIC POLYMORPHISM; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; HYPOTENSION; MORBID OBESITY; NAUSEA; PARESTHESIA; PHARMACOGENETICS; PRIORITY JOURNAL; SIDE EFFECT; SUICIDE ATTEMPT; TACHYCARDIA;

ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; CYTOCHROME P-450 CYP2D6; DEPRESSION; FEMALE; HUMANS; MIDDLE AGED; MODELS, CHEMICAL; POLYMORPHISM, GENETIC; RISK;

EID: 73449113301     PISSN: 00045632     EISSN: 00045632     Source Type: Journal    
DOI: 10.1258/acb.2009.009003     Document Type: Article

References (30)

1. Beijer HJ, de Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci 2002;24:46-54
2. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1997;277:301-6
3. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005;352:2211-21
4. Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet 2002;360:1155-62
5. Ereshefsky L, Dugan D. Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine. Depress Anxiety 2000;12(suppl. 1):30-44
6. Feighner JP. The role of venlafaxine in rational antidepressant therapy. J Clin Psychiatry 1994;55(suppl. A):62-8; discussion 9-70, 98-100
7. Shams ME, Arneth B, Hiemke C, et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther 2006;31:493-502
8. Veefkind AH, Haffmans PM, Hoencamp E. Venlafaxine serum levels and CYP2D6 genotype. Ther Drug Monit 2000;22:202-8
9. Levine B, Jenkins AJ, Queen M, Jufer R, Smialek JE. Distribution of venlafaxine in three postmortem cases. J Anal Toxicol 1996;20:502-5
10. Reeve HL, Nelson DP, Archer SL, Weir EK. Effects of fluoxetine, phentermine, and venlafaxine on pulmonary arterial pressure and electrophysiology. Am J Physiol 1999;276(Part 1):L213-9
11. Mazur JE, Doty JD, Krygiel AS. Fatality related to a 30-g venlafaxine overdose. Pharmacotherapy 2003;23:1668-72
12. Drent M, Singh S, Gorgels AP, et al. Drug-induced pneumonitis and heart failure simultaneously associated with venlafaxine. Am J Respir Crit Care Med 2003;167:958-61
13. Wijnen PAHM, Drent M, Nelemans PJ, et al. Role of cytochrome P450 polymorphisms in the development of pulmonary drug toxicity. Drug Saf 2008;31:1125-34
14. Burnett FE, Dinan TG. Venlafaxine. pharmacology and therapeutic potential in the treatment of depression. Hum Psychopharmacol 1998;13:153- 62
15. Hermann M, Hendset M, Fosaas K, Hjerpset M, Refsum H. Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele. Eur J Clin Pharmacol 2008;64:483-7
16. Grasmader K, Verwohlt PL, Rietschel M, et al. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol 2004;60:329-36
17. Blythe D, Hackett LP. Cardiovascular and neurological toxicity of venlafaxine. Hum Exp Toxicol 1999;18:309-13
18. Brogden RN, Heel RC, Speight TM, Avery GS. Metoprolol: a review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris. Drugs 1977;14:321-48
19. McAinsh J, Cruickshank JM. Beta-blockers and central nervous system side effects. Pharmacol Ther 1990;46:163-97
20. Ciusani E, Zullino DF, Eap CB, Brawand-Amey M, Brocard M, Baumann P. Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspects. J Psychopharmacol (Oxford, England) 2004;18:559-66
21. Liu X, Emery CJ, Laude E, et al. Adverse pulmonary vascular effects of high dose tricyclic antidepressants: acute and chronic animal studies. Eur Respir J 2002;20:344-52
22. Reznik I, Rosen Y, Rosen B. An acute ischaemic event associated with the use of venlafaxine: a case report and proposed pathophysiological mechanisms. J Psychopharmacol (Oxford, England) 1999;13:193-5
23. Colucci VJ, Berry BD. Heart failure worsening and exacerbation after venlafaxine and duloxetine therapy. Ann Pharmacother 2008;42:882-7
24. Khalifa M, Daleau P, Turgeon J. Mechanism of sodium channel block by venlafaxine in guinea pig ventricular myocytes. J Pharmacol Exp Ther 1999;291:280-4
25. Wijnen PA, Op den Buijsch RA, Drent M, et al. Review article: The prevalence and clinical relevance of cytochrome P450 polymorphisms. Aliment Pharmacol Ther 2007;26(suppl. 2):211-9
26. Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998;18:84-112
27. Birgersdotter UM, Wong W, Turgeon J, Roden DM. Stereoselective genetically-determined interaction between chronic flecainide and quinidine in patients with arrhythmias. Br J Clin Pharmacol 1992;33:275-80
28. Camus PH, Foucher P, Bonniaud PH, Ask K. Drug-induced infiltrative lung disease. Eur Respir J 2001;32:93s-100s
29. Jaquenoud E, van der Velden JW, Rentsch K, Eap CB, Baumann P. Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance. Drug Saf 2006;29:735-68
30. Clark DW, Donnelly E, Coulter DM, Roberts RL, Kennedy MA. Linking pharmacovigilance with pharmacogenetics. Drug Saf 2004;27:1171-84